JP2018523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523676A5
JP2018523676A5 JP2018508149A JP2018508149A JP2018523676A5 JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5 JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5
Authority
JP
Japan
Prior art keywords
histidine
hcl
aniflorumab
polysorbate
trehalose dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018508149A
Other languages
English (en)
Japanese (ja)
Other versions
JP6720293B2 (ja
JP2018523676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/047506 external-priority patent/WO2017031288A1/en
Publication of JP2018523676A publication Critical patent/JP2018523676A/ja
Publication of JP2018523676A5 publication Critical patent/JP2018523676A5/ja
Application granted granted Critical
Publication of JP6720293B2 publication Critical patent/JP6720293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018508149A 2015-08-19 2016-08-18 安定な抗ｉｆｎａｒ１製剤 Active JP6720293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
US62/207,164 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020104494A Division JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤

Publications (3)

Publication Number Publication Date
JP2018523676A JP2018523676A (ja) 2018-08-23
JP2018523676A5 true JP2018523676A5 (enExample) 2020-04-23
JP6720293B2 JP6720293B2 (ja) 2020-07-08

Family

ID=58052002

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018508149A Active JP6720293B2 (ja) 2015-08-19 2016-08-18 安定な抗ｉｆｎａｒ１製剤
JP2020104494A Active JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤
JP2022031581A Pending JP2022066345A (ja) 2015-08-19 2022-03-02 安定な抗ｉｆｎａｒ１製剤
JP2024140769A Pending JP2024161043A (ja) 2015-08-19 2024-08-22 安定な抗ｉｆｎａｒ１製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020104494A Active JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤
JP2022031581A Pending JP2022066345A (ja) 2015-08-19 2022-03-02 安定な抗ｉｆｎａｒ１製剤
JP2024140769A Pending JP2024161043A (ja) 2015-08-19 2024-08-22 安定な抗ｉｆｎａｒ１製剤

Country Status (23)

Country Link
US (1) US10125195B2 (enExample)
EP (3) EP3769781B1 (enExample)
JP (4) JP6720293B2 (enExample)
KR (4) KR102168005B1 (enExample)
CN (1) CN107921109A (enExample)
AU (3) AU2016308262C1 (enExample)
CA (1) CA2995222C (enExample)
CY (2) CY1123657T1 (enExample)
DK (2) DK3769781T5 (enExample)
ES (2) ES2947488T3 (enExample)
FI (1) FI3769781T3 (enExample)
HR (2) HRP20201297T1 (enExample)
HU (2) HUE061985T2 (enExample)
IL (1) IL257279B2 (enExample)
LT (2) LT3769781T (enExample)
PL (2) PL3337502T3 (enExample)
PT (2) PT3337502T (enExample)
RS (2) RS64263B1 (enExample)
RU (1) RU2731737C2 (enExample)
SG (1) SG10202106970XA (enExample)
SI (2) SI3337502T1 (enExample)
SM (2) SMT202000483T1 (enExample)
WO (1) WO2017031288A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
HUE070947T2 (hu) * 2019-11-11 2025-07-28 Astrazeneca Ab I-es típusú interferon gátlása szisztémás lupus erythematosusban
EP4566667A3 (en) 2020-05-29 2025-09-03 AstraZeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
IL299215A (en) 2020-06-25 2023-02-01 Medimmune Ltd Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
CA3204307A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
RS64821B1 (sr) 2021-04-23 2023-12-29 Astrazeneca Ab Režim doziranja anti-ifnar1 za subkutane injekcije
WO2022223771A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
BR112023021868A2 (pt) 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
EP4337696A1 (en) 2021-05-12 2024-03-20 Astrazeneca AB Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
IL310241A (en) 2021-07-27 2024-03-01 Astrazeneca Ab Lupus treatment
US20250122294A1 (en) 2021-10-04 2025-04-17 Astrazeneca Ab Treatment of lupus
CA3234358A1 (en) * 2021-10-29 2023-05-04 Intas Pharmaceuticals Ltd. Stable lyophilized formulation of an anti-.alpha.4.beta.7 antibody
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
IN202221038828A (enExample) * 2022-07-06 2024-01-12
WO2024079241A1 (en) 2022-10-13 2024-04-18 Astrazeneca Ab Treatment of lupus
IL324676A (en) 2023-05-19 2026-01-01 Astrazeneca Ab Lupus treatment
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
JP5160887B2 (ja) * 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0721097A2 (pt) * 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
EP2250279B1 (en) * 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1 antibodies with reduced fc ligand affinity
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
MY171920A (en) * 2011-10-12 2019-11-07 Ascendis Pharma Ophthalmology Div A/S Prevention and treatment of ocular conditions
CN104023748B (zh) 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN106421782A (zh) * 2012-10-25 2017-02-22 米迪缪尼有限公司 稳定的低粘度抗体配制品
JP2016519145A (ja) * 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
JP2017502922A (ja) 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
BR112017003419A2 (pt) 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
US20180000932A1 (en) 2014-12-31 2018-01-04 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija

Similar Documents

Publication Publication Date Title
JP2018523676A5 (enExample)
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EP3316928A4 (en) AUTOMATIC INJECTORS FOR THE ADMINISTRATION OF A MEDICAMENT IN A PREPARED SYRINGE
HRP20211371T1 (hr) Stabilne, vodene formulacije protutijela
JP2015057451A5 (enExample)
AR107014A1 (es) Formulación farmacéutica acuosa
EA201792591A1 (ru) Фармацевтические препараты
HRP20221263T1 (hr) Ciklički di-nukleotidni spojevi i postupci uporabe
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
JP2015110588A5 (enExample)
AR092401A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr)
JP2019516735A5 (enExample)
EA201891606A1 (ru) Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
JP2016510326A5 (enExample)
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
JP2016515623A5 (enExample)
EA201890788A1 (ru) Препараты оланзапина с замедленным высвобождением
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
JP2014058509A5 (enExample)